Baird served as co-manager on this offering
AboutReata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) recently completed an underwritten public offering of 2,760,000 shares of its common stock, including 360,000 shares sold upon full exercise of the overallotment option, at a price to the public of $183.00 per share. The gross proceeds to Reata from the offering are expected to be $505.1 million.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (bardoxolone) and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency. Reata Pharmaceuticals, Inc. is headquartered in Plano, Texas.
CONTACT US TO LEARN MORE
- November 2019
- Reata Pharmaceuticals, Inc.
- Target Location
- North America